Diana Ernst, RPh

Editorial Director https://www.clinicaladvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Cardiovascular Disease Information Center

Farxiga Approval Expands Use to More Patients With Heart Failure

Diana Ernst, RPh

May 10, 2023

Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.

Neurology Information Center

Systemic, Inhaled Glucocorticoid Use Linked to Changes in the Brain

Diana Ernst, RPh

September 7, 2022

To investigate the association between glucocorticoids and and brain structure changes, researchers used data from the UK Biobank.

Cardiovascular Disease Information Center

First Anticoagulant Approved to Treat Symptomatic VTE in Pediatric Patients

Diana Ernst, RPh

May 17, 2019

The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.

HIV/AIDS Information Center

NDA for Once-Monthly Injectable HIV Treatment Submitted to FDA

Diana Ernst, RPh

May 16, 2019

The New Drug Application (NDA) for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for patients with HIV-1 infection has been submitted to the Food and Drug Administration (FDA).

Mood Disorder Information Center

Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation

Diana Ernst, RPh

May 14, 2019

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia.

HIV/AIDS Information Center

CDC to Receive Large Donation of PrEP Medication to Help With HIV Prevention

Diana Ernst, RPh

May 13, 2019

Truvada is approved in combination with safer sex practices for HIV-1 PrEP to reduce the risk of sexually acquired HIV-1.

Gastroenterology Information Center

BLA for Subcutaneous Formulation of Vedolizumab Submitted for FDA Review

Diana Ernst, RPh

May 10, 2019

The FDA has accepted for review the Biologics License Application (BLA) for a subcutaneous (SC) formulation of vedolizumab as maintenance treatment for adult patients with moderately to severely active ulcerative colitis (UC).

Surgery Information Center

FDA Passes on Barhemsys NDA Again Due to Facility Issues

Diana Ernst, RPh

May 6, 2019

The FDA has issued a second complete response letter to Acacia Pharma regarding the New Drug Application for Barhemsys (amisulpride injection).

Nephrology Information Center

Recommendations for the Evaluation, Management of Recurrent UTI in Women Released

Diana Ernst, RPh

May 2, 2019

A new clinical guideline on the diagnosis and treatment of recurrent urinary tract infections in women was released by the AUA together with the Canadian Urological Association, and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction.

Rheumatology Information Center

First Treatment for Children With Systemic Lupus Erythematosus Gets FDA Approval

Diana Ernst, RPh

May 1, 2019

The Food and Drug Administration (FDA) has approved the intravenous (IV) formulation of Benlysta (belimumab; GlaxoSmithKline) for the treatment of pediatric patients ≥5 years old with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

Next post in Rheumatology Information Center